Cymax IL-8 (human) ELISA Kit
|Application Set||Compound Screening|
|Range||0.78 pg/ml - 50 pg/ml|
Cell Culture Supernatant
|Other Product Data||
Click here for Original Manufacturer Product Datasheet
|Declaration||Manufactured by AbFrontier|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||+4°C|
Any unused reconstituted standard should be discarded or frozen at -80℃.
Standard can be frozen and thawed one time only without loss of immunoreactivity.
|Product Specification Sheet|
Interleukin-8 (IL-8) was originally discovered as a neutrophil chemotactic and activating factor and is a member of the α (CXC) subfamily of chemokines (including also platelet factor 4, GRO, IP-10, etc.). Many cell types, including monocyte/macrophages, T cells, neutrophils, fibroblasts, endothelial cells, keratinocytes, hepatocytes, chondrocytes and various tumor cell lines, produce IL-8 in response to a wide variety of proinflammatory stimuli such as exposure to IL-1, TNF, LPS and viruses. IL-8 has a wide range of other proinflammatory effects. It is a potent chemoattractant for neutrophils and causes degranulation of neutrophil specific granules and azurophilic granules. IL-8 induces expression of the cell adhesion molecules CD11/CD18 and enhances the adherence of neutrophils to endothelial cells and subendothelial matrix proteins. Besides neutrophils, IL-8 is also chemotactic for basophils, T cells and eosinophils. IL-8 has been reported to be a co-mitogen for keratinocytes and was also shown to be an autocrine growth factor for melanoma cells. IL-8 was also reported to be angiogenic both in vivo and in vitro.
- Histone deacetylase 6 regulated expression of IL-8 is involved in the doxorubicin (Dox) resistance of osteosarcoma cells via modulating ABCB1 transcription: M. Cheng, et al.; Eur. J. Pharmacol. 840, 1 (2018)